{
    "clinical_study": {
        "@rank": "1292", 
        "arm_group": [
            {
                "arm_group_label": "CTAP101 30 \u03bcg capsules", 
                "arm_group_type": "Active Comparator", 
                "description": "1 CTAP101 30 \u03bcg capsule daily at bedtime"
            }, 
            {
                "arm_group_label": "CTAP101 60 \u03bcg capsules", 
                "arm_group_type": "Active Comparator", 
                "description": "2 CTAP101 30 \u03bcg capsules daily at bedtime"
            }, 
            {
                "arm_group_label": "CTAP101 30 \u03bcg sugar pill capsule", 
                "arm_group_type": "Placebo Comparator", 
                "description": "1 CTAP101 sugar pill capsule daily at bedtime"
            }, 
            {
                "arm_group_label": "CTAP101 60 \u03bcg sugar pill capsules", 
                "arm_group_type": "Placebo Comparator", 
                "description": "2 CTAP101 30 \u03bcg sugar pill capsules daily at bedtime"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will evaluate the efficacy of CTAP101 Capsules versus placebo in reducing intact\n      parathyroid hormone (iPTH) by at least 30% from pretreatment baseline; safety and\n      tolerability of CTAP101 will also be evaluated"
        }, 
        "brief_title": "Safety and Efficacy of CTAP101 Capsules to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency", 
        "completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Chronic Kidney Disease", 
            "Secondary Hyperparathyroidism (SHPT)", 
            "Vitamin D Insufficiency"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hyperparathyroidism", 
                "Hyperparathyroidism, Secondary", 
                "Kidney Diseases", 
                "Renal Insufficiency, Chronic", 
                "Kidney Failure, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Urinary albumin excretion \u2264 3000 mcg/mg of creatinine\n\n          2. Stage 3 or 4 CKD\n\n          3. Plasma iPTH: \u2265 85 pg/mL and < 500 pg/mL\n\n          4. Serum Ca: \u2265 8.4 mg/dL and < 9.8 mg/dL\n\n          5. Serum P: \u2265 2.0 mg/dL and < 5.0 mg/dL\n\n          6. Serum 25-hydroxyvitamin D: \u2265 10 ng/mL and < 30 ng/mL.\n\n          7. Stable dose of Vitamin D therapy \u2264 1600 IU/day and receiving same dose for at least 2\n             months\n\n        Exclusion Criteria:\n\n          1. History of kidney transplant or parathyroidectomy\n\n          2. Spot urine calcium:creatinine ratio > 0.2 (>200 mg/g Cr)\n\n          3. Current serious illness, such as malignancy, HIV, liver disease, cardiovascular event\n             or hepatitis\n\n          4. Currently on dialysis\n\n          5. Use of pharmacological dose of ergocalciferol or cholecalciferol (\u2265 50,000 IU mcg per\n             month) during the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "210", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 23, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01651000", 
            "org_study_id": "CTAP101-CL-3001"
        }, 
        "intervention": [
            {
                "arm_group_label": "CTAP101 30 \u03bcg capsules", 
                "description": "Subjects will take 1 capsule (CTAP101 30 \u03bcg or matching placebo)daily at bedtime for 12 weeks.  After 12 weeks, the dose may be increased in a blinded fashion based on dose titration criterion.", 
                "intervention_name": "CTAP101 30 \u03bcg capsules", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "CTAP101 60 \u03bcg capsules", 
                "description": "Subjects will take 1 capsule (CTAP101 30 \u03bcg or matching placebo)daily at bedtime for 12 weeks.  After 12 weeks, the dose may be increased in a blinded fashion based on dose titration criterion.", 
                "intervention_name": "CTAP101 60 \u03bcg capsules", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "CTAP101 30 \u03bcg sugar pill capsule", 
                "description": "Subjects will take 1 capsule (CTAP101 30 \u03bcg or matching placebo)daily at bedtime for 12 weeks.  After 12 weeks, the dose may be increased in a blinded fashion based on dose titration criterion.", 
                "intervention_name": "CTAP101 30 \u03bcg sugar pill capsule", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "CTAP101 60 \u03bcg sugar pill capsules", 
                "description": "Subjects will take 1 capsule (CTAP101 30 \u03bcg or matching placebo)daily at bedtime for 12 weeks.  After 12 weeks, the dose may be increased in a blinded fashion based on dose titration criterion.", 
                "intervention_name": "CTAP101 60 \u03bcg sugar pill capsules", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Contraceptives, Oral", 
                "Vitamin D", 
                "Ergocalciferols", 
                "Vitamins"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Parathyroid Diseases", 
            "Renal Insufficiency", 
            "Kidney Failure, Chronic", 
            "Hyperparathyroidism, Secondary", 
            "Vitamin D", 
            "Hyperparathyroidism", 
            "Kidney Diseases", 
            "Kidney Failure", 
            "Renal Insufficiency, Chronic"
        ], 
        "lastchanged_date": "May 21, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Bannockburn", 
                    "country": "United States", 
                    "state": "Illinois", 
                    "zip": "60015"
                }, 
                "name": "Cytochroma Inc."
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of CTAP101 Capsules to Treat Secondary Hyperparathyroidism in Subjects With Stage 3 or 4 Chronic Kidney Disease and Vitamin D Insufficiency", 
        "other_outcome": {
            "measure": "Changes in efficacy and safety based on weight, age, gender, race, dose, CKD stage, SHPT severity, use of Vitamin D supplements, use of Ca supplements, baseline serum total 25D and eGFR", 
            "safety_issue": "Yes", 
            "time_frame": "Approximately 6 months"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Primary Objectives:\nThe primary objectives of this study are:\nTo evaluate the efficacy of CTAP101 Capsules versus placebo in reducing plasma intact parathyroid hormone (iPTH) by at least 30% from pre-treatment baseline", 
                "measure": "Changes of at least 30% in plasma iPTH from pretreatment baseline", 
                "safety_issue": "No", 
                "time_frame": "Approximately 6 months"
            }, 
            {
                "description": "To investigate the safety and tolerability of CTAP101 Capsules through changes in adverse events, physical examinations,vital signs, clinical laboratory tests, vital signs, and 12-lead ECGs", 
                "measure": "Changes in safety and tolerability to CTAP101 capsules", 
                "safety_issue": "Yes", 
                "time_frame": "Approximately 6 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01651000"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To evaluate the efficacy of CTAP101 capsules versus placebo in increasing serum total 25D to \u2265 30 ng/ML", 
                "measure": "Changes in serum total 25D to \u2265 30 ng/ML", 
                "safety_issue": "No", 
                "time_frame": "Approximately 6 months"
            }, 
            {
                "measure": "Changes in hypercalciuria, hypercalcemia and drug-related hyperphosphatemia.", 
                "safety_issue": "Yes", 
                "time_frame": "Approximately 6 months"
            }
        ], 
        "source": "Cytochroma Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Cytochroma Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}